METHOD FOR DETERMINING RISK OF DEVELOPING ACUTE CEREBROVASCULAR ACCIDENT IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION FOR 12 MONTHS AFTER COVID-19 Russian patent published in 2024 - IPC G01N33/68 G01N33/573 

FIELD: medicine; immunology; cardiology; neurology.

SUBSTANCE: invention can be used to determine the risk of developing acute cerebrovascular accident in patients with essential arterial hypertension for 12 months after COVID-19. Levels of soluble leukemia inhibition factor receptor (sLIFr) are measured in blood at 08:00 and 20:00 of the same day, in pg/ml. Blood sampling day is selected from 10th to 30th day after the first negative result of SARS-CoV-2 RNA PCR. Coefficient reflecting the ratio of sLIFr at 20:00 to sLIFr at 08:00 in percent is calculated. High risk is determined if the patient’s blood serum sLIFr level is 5,000 pg/ml and more with a subsequent increase at 20:00 in the sLIFr level by 50% and more. Average risk is determined at 08:00 at sLIFr level 5,000 pg/ml and more with the subsequent increase in the sLIFr level at 20:00 to 50%. Low risk is determined if the sLIFr level at 08:00 is less than 5,000 pg/ml regardless of the sLIFr dynamics at 20:00.

EFFECT: method provides the possibility of increasing the accuracy of calculating the individual risk of developing a lethal and non-lethal acute cerebrovascular accident in patients with essential arterial hypertension for 12 months after suffering COVID-19, by studying the level of sLIFr in blood serum at 08:00 and 20:00 on the same day in the period of early recovery—day of blood sampling in patients suffering new coronavirus infection in period from 10 to 30 days after 1st negative PCR for determination of RNA SARS-CoV-2.

1 cl, 1 tbl, 3 ex